G Eichenbaum
Overview
Explore the profile of G Eichenbaum including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
46
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Labib R, Bury D, Boisleve F, Eichenbaum G, Girard S, Naciff J, et al.
Regul Toxicol Pharmacol
. 2018 Feb;
94:245-251.
PMID: 29410076
Salicylic acid (SA) has a long history of safe use as ingredient in topical cosmetic products. In 2016, the Committee for Risk Assessment of the European Chemicals Agency proposed to...
2.
Eichenbaum G, Zhou J, Kelley M, Roosen W, Costa-Giomi P, Louden C, et al.
Regul Toxicol Pharmacol
. 2014 Apr;
69(2):187-200.
PMID: 24680767
The development path described for JNJ-26489112 provides perspectives on interpretation of retinal effects observed in nonclinical studies and their implications for clinical development. JNJ-26489112 is a CNS-active investigational drug that...
3.
Eichenbaum G, Zhou J, De Smedt A, De Jonghe S, Looszova A, Arien T, et al.
J Pharmacol Toxicol Methods
. 2013 Aug;
68(3):394-406.
PMID: 23933112
Introduction: Evaluation of infusion site tolerability is required for the development of intravenous formulations of New Molecular Entities and is of particular importance for investigational drugs that have the potential...
4.
Eichenbaum G, Pugsley M, Gallacher D, Towart R, McIntyre G, Shukla U, et al.
Br J Pharmacol
. 2012 Feb;
166(5):1694-707.
PMID: 22289150
Background And Purpose: JNJ-Q2, a novel broad-spectrum fluoroquinolone with anti-methicillin-resistant Staphylococcus aureus activity, was evaluated in a comprehensive set of non-clinical and clinical cardiovascular safety studies. The effect of JNJ-Q2...
5.
Eichenbaum G, Damsch S, Looszova A, Vandenberghe J, Van den Bulck K, Roels K, et al.
J Appl Toxicol
. 2010 Nov;
31(4):342-54.
PMID: 21089156
Unscheduled mortality preceded by adverse respiratory clinical signs in rats dosed by oral gavage may not only be caused by technical gavage error or systemic toxicity but may also be...
6.
Eichenbaum G, Johnson M, Kirkland D, ONeill P, STELLAR S, Bielawne J, et al.
Regul Toxicol Pharmacol
. 2009 Jun;
55(1):33-42.
PMID: 19500632
According to the 2008 US FDA (draft) and 2006 EMEA guidance documents for genotoxic impurities, an impurity that is positive in an in vitro genotoxicity study, in the absence of...
7.
Eichenbaum G, Pollock-Dove C, Nguyen J, Li S, Evans J, Borghys H, et al.
J Pharm Sci
. 2006 Feb;
95(4):883-95.
PMID: 16489607
In this paper, we present a preclinical approach for evaluating the feasibility of applying controlled-release (CR) oral drug delivery to increase the duration of exposure and lower the C(max) of...
8.
Needham D, Mills J, Eichenbaum G
Faraday Discuss
. 2000 May;
(111):103-10; discussion 137-57.
PMID: 10822603
The exchange of the protonatable polymer, poly(2-ethylacrylic acid) (PEAA), has been studied with vesicle membranes containing cholesterol from 0 to 60 mol% or PEG2000-lipid (5 mol%). The release of an...
9.
Oortgiesen M, Veronesi B, Eichenbaum G, Kiser P, Simon S
Am J Physiol Lung Cell Mol Physiol
. 2000 Apr;
278(4):L683-95.
PMID: 10749745
Residual oil fly ash (ROFA) is an industrial pollutant that contains metals, acids, and unknown materials complexed to a particulate core. The heterogeneous composition of ROFA hampers finding the mechanism(s)...